THTX | Theratechnologies Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2500 - 1.2900
52 Week Range	0.8800 - 2.5800
Beta	1.66
Implied Volatility	362.40%
IV Rank	54.87%
Day's Volume	30,452
Average Volume	34,796
Shares Outstanding	45,980,018
Market Cap	58,854,423
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2009-02-13

Valuation
Profitability
Growth
Health
P/E Ratio	-32.00
Forward P/E Ratio	N/A
EPS	-0.04
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	103
Country	Canada
Website	THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

THTX's peers: OPT, CNTA, NUVL, TARS, GNFT, VRCA, LIAN, IVA, EWTX, VIGL, APLT, LYRA, STTK, VINC, BCAB, PMVP, ELYM, MNOV, PHVS, PEPG

*Chart delayed

Analyzing fundamentals for THTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see THTX Fundamentals page.

Watching at THTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on THTX Technicals page.